Strategic focus Target neurology and neuroinflammation markets with CRO/partnering discussions around cromolyn-based therapies for Alzheimer's disease, ALS, and post-ischemic stroke cognitive impairment, emphasizing late-stage clinical potential and safety profile.

Funding leverage Engage investors and partners around AZTherapies’ substantial funding history (Series C1 and Series C) and ongoing clinical development to support co-development or licensing deals, signaling strong financial backing and milestones.

Leadership access Leverage the presence of experienced executives and a renowned scientific advisory board to open high-level conversations with pharma partners, academic collaborators, and potential licensees seeking credibility and scientific rigor.

Global expansion Position partnerships to accelerate global clinical trials and manufacturing scale, citing early manufacturing leadership hires and CMC focus to streamline tech transfer, regulatory filings, and supply chain readiness.

Technology dialogue Highlight the multi-modal, cromolyn-centric approach and brain immune modulation as a differentiator, offering opportunities for strategic collaborations on biomarker development, companion diagnostics, and real-world evidence generation.